(Q84569356)

English

Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432

scientific article published on 15 September 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432 (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Masatoshi Aoki

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Shugo Ueda

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Hiroyoshi Nishikawa

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Shigehisa Kitano

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Michiko Hirayama

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Hiroaki Ikeda

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Hideki Toyoda

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Kyosuke Tanaka

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Michiyuki Kanai

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Arimichi Takabayashi

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Hiroshi Imai

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Taizo Shiraishi

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Eiichi Sato

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Hisashi Wada

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Eiichi Nakayama

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Yoshiyuki Takei

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Naoyuki Katayama

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Shinichi Kageyama

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

publication date

15 September 2009

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

27

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

49

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

6854-6861

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

NY-ESO-1 expression and immunogenicity in esophageal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

A survey of the humoral immune response of cancer patients to a panel of human tumor antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

The nature and consequences of intra- and inter-vaccine interference

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

Clinically relevant vaccine-vaccine interactions: a guide for practitioners.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

T cells compete for access to antigen-bearing antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.018

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.09.018

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19761832%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84569356&oldid=2148638618"